Skip to main content

Table 3 Change in migraine frequency during the first week of treatment versus the last week before treatment in the 82 patients who completed the 12-week follow-up

From: GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

 

All (n = 82)

HFEM (n = 35)

CM (n = 47)

Migraine days during last week before treatment

4.3 ±1.9

2.5±0.7

5.7±1.4

Migraine days during the first week of treatment

2.2±2.3

1.0±1.2

2.8 ±2.4

Δ

-2.5±2.0

-1.5±0.5

-3.1±2.1

p-value

<0.001

<0.001

<0.001

  1. Abbreviations: All overall migraine population, HFE high-frequency episodic migraine, CM chronic migraine
  2. *p-value of nonparametric test for two paired samples